Astellas Pharma (ALPMY) announced the U.S. Food and Drug Administration approved Izervay for the treatment of geographic atrophy, or GA, secondary to age-related macular degeneration, or AMD, on August 4. “Izervay, a new complement C5 inhibitor, is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials,” the company stated. Izervay, formerly Zimura/ACP, from Astellas will be a competitor in GA to Apellis’ (APLS) Syfovre.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis downgraded to Neutral from Overweight at JPMorgan
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Apellis price target lowered to $70 from $115 at Baird
- Apellis downgraded to Neutral at BofA on wait and see approach to safety issues